RxDoctor Payments Data

Patrick Drechsler

Medical · Wausau, WINPI 1942852504

Payments from drug & device makers

What this record shows

12 manufacturers reported payments, led by Inari Medical, Inc. at 50.1% of the total. Reporting peaked in 2024 at $3,289 and has fallen 90.8% since, to $303 in 2025. Among medical clinicians in WI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$5,446in general payments, 2019–2025

Across 32 payments — averaging $170.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inari Medical, Inc.$3K
  • Boston Scientific$1K
  • Abbott$635
  • Penumbra, Inc.$248
  • Boehringer Ingelheim$181
  • Abiomed$149
  • plus $472 from 6 others

What the payments were for

  • Travel & lodging$3,20559%
  • Food & beverage$2,24141%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,446 in reported general payments places this provider in the 95th percentile of 247 medical providers in Wisconsin.

See all medical providers in Wisconsin

Medicare billing

Part B allowed, 2024
$44,266
Medicare patients
329
Services billed
470

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban249$259,675
EntrestoSacubitril/Valsartan287$251,906
JardianceEmpagliflozin148$143,168
Repatha SureclickEvolocumab16$13,728
Bumetanide137$5,733
Metoprolol Succinate449$5,725
NexletolBempedoic Acid13$5,156
Ranolazine ErRanolazine27$5,151
Potassium Chloride79$3,705
Rosuvastatin Calcium172$3,434
Ezetimibe127$2,888
Atorvastatin Calcium364$2,781
ClopidogrelClopidogrel Bisulfate114$1,839
Carvedilol192$1,417
Losartan Potassium197$1,268

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$181$143,168148 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 247 medical providers in Wisconsin.

Other medical in Wausau

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →